Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederotsuka.co.jp
Otsuka Pharmaceutical Co., Ltd. News Releases
Get the latest updates from Otsuka Pharmaceutical Co., Ltd. News Releases directly as they happen.
Follow now 90 followers
Latest posts
Last updated 11 days ago
Otsuka Launches Frailty Prevention Support VR as Newest Content in FACEDUO VR Program Portfolio - Enables earlier detection of frailty to support health maintenance and prevent or defer the need for nursing care -
11 days ago
Otsuka Launches Frailty Prevention Support VR as Newest Content in FACEDUO VR...
Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression
17 days ago
Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of...
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
18 days ago
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for...
Donidalorsen Receives Positive CHMP Opinion for the Prevention of Hereditary Angioedema Attacks
26 days ago
Donidalorsen Receives Positive CHMP Opinion for the Prevention of Hereditary Angioedema Attacks
Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week 2025 Showed Proteinuria Reduction through 12 Months for the Treatment of Immunoglobulin A Nephropathy (IgAN) Trial Interim Analysis Outcomes Published in New England Jour
about 1 month ago
Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week...
Otsuka Announces First Participants Enrolled in Phase 3 Clinical Trial Evaluating Investigational Compound Quabodepistat for Drug-resistant Pulmonary Tuberculosis
about 1 month ago
Otsuka Announces First Participants Enrolled in Phase 3 Clinical Trial Evaluating Investigational...
Otsuka Signs Joint Research Agreement in Japan with National Cerebral and Cardiovascular Center -Purpose Is to Evaluate Salt Reduction Behavior Change in Heart Disease Patients Using a Nutritional Monitoring App-
about 1 month ago
Otsuka Signs Joint Research Agreement in Japan with National Cerebral and Cardiovascular...
Otsuka Enters into Licensing Agreement for Ophthalmic Gene Therapy Drug Candidate 4D-150 (Anti-VEGF agent) ‐ Acquires Exclusive Development and Commercialization Rights for Asia-Oceania Region, Including Japan, from 4DMT ‐
about 1 month ago
Otsuka Enters into Licensing Agreement for Ophthalmic Gene Therapy Drug Candidate 4D-150...
Research on Work Productivity Among Japanese Workers Published in the Journal of Occupational Health — Visualizing the Impact of a Range of Diseases on Productivity Using Large-Scale Data —
2 months ago
Research on Work Productivity Among Japanese Workers Published in the Journal of...
Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
3 months ago
Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA...
Otsuka Receives Approval in Japan for NEXLETOL®as a Treatment for Hypercholesterolemia
3 months ago
Otsuka Receives Approval in Japan for NEXLETOL®as a Treatment for Hypercholesterolemia